| Fishkill Center For Rehab & Nursing Lthhcp | |
| 22 Robert R Kasin Way, Beacon, New York 12508 | |
| (845) 831-8704 | |
| Name | Fishkill Center For Rehab & Nursing Lthhcp |
|---|---|
| Location | 22 Robert R Kasin Way, Beacon, New York |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Medical Social Services |
| Medicare ID | 337218 |
| Ownership Type | Voluntary Non-profit - Private |
| Service Area Zip Codes | 12501, 12508, 12512, 12514, 12522, 12524, 12531, 12533, 12538, 12540, 12545, 12546, 12564, 12567, 12569, 12570, 12571, 12572, 12578, 12580, 12581, 12582, 12583, 12585, 12590, 12592, 12594, 12601, 12603 |
| NPI Number | 1083750467 |
| Organization Name | ELANT AT FISHKILL, INC |
| Address | 22 Robert R Kasin Way, Beacon, NY 12508 |
| Phone Number | 845-291-3700 |
News Archive
Cytochroma today announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated.
The challenges in providing psychotherapy to individuals with autism spectrum disorders (ASD) who also are struggling with their gender identity are explored in two case studies of high-functioning persons with diagnoses of ASD and gender dysphoria (GD).
PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF).
Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.
› Verified 7 days ago
| NPI Number | 1841728664 |
| Organization Name | YERTLE OPERATIONS LLC |
| Doing Business As | FISHKILL CENTER FOR REHABILITATION & NURSING |
| Address | 22 Robert R Kasin Way, Beacon, NY 12508 |
| Phone Number | 845-831-8704 |
News Archive
Cytochroma today announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated.
The challenges in providing psychotherapy to individuals with autism spectrum disorders (ASD) who also are struggling with their gender identity are explored in two case studies of high-functioning persons with diagnoses of ASD and gender dysphoria (GD).
PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF).
Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.
› Verified 7 days ago
| Quality Rating: |
News Archive
Cytochroma today announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated.
The challenges in providing psychotherapy to individuals with autism spectrum disorders (ASD) who also are struggling with their gender identity are explored in two case studies of high-functioning persons with diagnoses of ASD and gender dysphoria (GD).
PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF).
Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.
› Verified 7 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 74.2 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 95.7 | 98.6 |
| How often the home health team checked patients’ risk of falling | 83.6 | 99.6 |
| How often the home health team checked patients for depression | 75.3 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 67.1 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 48.1 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 80.8 | 96.4 |
News Archive
Cytochroma today announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated.
The challenges in providing psychotherapy to individuals with autism spectrum disorders (ASD) who also are struggling with their gender identity are explored in two case studies of high-functioning persons with diagnoses of ASD and gender dysphoria (GD).
PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF).
Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.
› Verified 7 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 54 | 79.6 |
| How often patients got better at getting in and out of bed | 75.2 | 81.1 |
| How often patients got better at bathing | 63 | 82.3 |
| How often patients’ breathing improved | 62.2 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 82.6 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 56 | 75 |
| How often home health patients had to be admitted to the hospital | 20.4 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 14.9 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 89.5 | 94 |
News Archive
Cytochroma today announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated.
The challenges in providing psychotherapy to individuals with autism spectrum disorders (ASD) who also are struggling with their gender identity are explored in two case studies of high-functioning persons with diagnoses of ASD and gender dysphoria (GD).
PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF).
Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.
› Verified 7 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Cytochroma today announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated.
The challenges in providing psychotherapy to individuals with autism spectrum disorders (ASD) who also are struggling with their gender identity are explored in two case studies of high-functioning persons with diagnoses of ASD and gender dysphoria (GD).
PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF).
Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.
› Verified 7 days ago
The patient survey data of Fishkill Center For Rehab & Nursing Lthhcp is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 83 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 80 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 68 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 74 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 61 | 78 |
News Archive
Cytochroma today announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated.
The challenges in providing psychotherapy to individuals with autism spectrum disorders (ASD) who also are struggling with their gender identity are explored in two case studies of high-functioning persons with diagnoses of ASD and gender dysphoria (GD).
PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF).
Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.
› Verified 7 days ago
Fishkill Center For Rehab & Nursing Lthhcp Location: 22 Robert R Kasin Way, Beacon, New York 12508 Ratings: Phone: (845) 831-8704 |